U.S. markets close in 2 hours 26 minutes
  • S&P 500

    3,898.96
    -2.86 (-0.07%)
     
  • Dow 30

    31,574.78
    +39.27 (+0.12%)
     
  • Nasdaq

    13,495.13
    -93.69 (-0.69%)
     
  • Russell 2000

    2,251.43
    -23.89 (-1.05%)
     
  • Crude Oil

    60.68
    +0.04 (+0.07%)
     
  • Gold

    1,734.90
    +11.90 (+0.69%)
     
  • Silver

    26.87
    +0.19 (+0.72%)
     
  • EUR/USD

    1.2092
    +0.0032 (+0.27%)
     
  • 10-Yr Bond

    1.4220
    -0.0240 (-1.66%)
     
  • GBP/USD

    1.3973
    +0.0053 (+0.38%)
     
  • USD/JPY

    106.7490
    +0.0190 (+0.02%)
     
  • BTC-USD

    47,909.20
    -1,113.58 (-2.27%)
     
  • CMC Crypto 200

    960.90
    -25.75 (-2.61%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

UPDATE 3-Vaccine manufacturing deals power Emergent BioSolutions profit beat

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

(Adds details from post earnings call)

Feb 18 (Reuters) - Emergent BioSolutions Inc beatfourth-quarter profit expectations on Thursday, benefiting frommanufacturing deals to help produce COVID-19 vaccines andtherapeutics.

The company has entered into more than seven manufacturingcollaborations, including with AstraZeneca Plc, Johnson& Johnson, Novavax, Vaxart Inc,Humanigen Inc, since the outbreak of the pandemic.

The company said it has set up a large-scale manufacturinginfrastructure, which will help it produce and supply drugsubstance for the vaccine candidates on time.

"We're right online with doing that, timing-wise, as well ascapability for both Johnson & Johnson and AstraZenecaPlc," Chief Executive Robert Kramer said on a conferencecall with analysts.

"Specific to J&J, their short-term goal is to provide asmany as 100 million doses to the U.S. government in the firsthalf of 2021. And we're right on schedule to support that."

Revenue from the company's contract development andmanufacturing (CDMO) unit rose to $199.1 million in the quarterfrom $25.5 million a year ago.

"Expect our CDMO business to continue to be a significantcontributor to our future growth and expansion," Kramer said.

Excluding items, Emergent earned $3.67 per share in thequarter ended Dec. 31, ahead of the analysts' average estimateof $3.19.

Shares of the Gaithersburg, Maryland-based company were up1.52% in extended trading.(Reporting by Mrinalika Roy in Bengaluru; Editing by ShaileshKuber and Arun Koyyur)